Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 10Metastatic Castration-resistant Prostate Cancer 2Prostatic Neoplasms, Castration-Resistant 1Metastatic Hormone Naive Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Prednisone 3Abiraterone Acetate 3niraparib 2enzalutamide 2gallium 68 PSMA-11 1Rosuvastatin Calcium 1Pluvicto 1Pioglitazone 1Gonadotropin-Releasing Hormone 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Prostatic Neoplasms, Castration-Resistant × Pluvicto × Clear all
NCT07047118 2026-05-01

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Novartis

Phase 2 Active not recruiting
138 enrolled
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡